No significant difference between LAMAs and LABAs in treating persistent asthma, research finds

Data from 15 randomised trials show that while long-acting muscarinic antagonists reduced exacerbation risk by a third, there was no significant improvement compared with long-acting beta-agonists.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research